SEARCH:   Advanced

Blood, 16 July 2009, Vol. 114, No. 3, pp. 522-525. Prepublished online as a Blood First Edition Paper on March 30, 2009; DOI 10.1182/blood-2008-12-193458. This Article Full Text (PDF) All Versions of this Article: blood-2008-12-193458v1 114/3/522    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Reece, D. Articles by Bahlis, N. J. Search for Related Content PubMed PubMed Citation Articles by Reece, D. Articles by Bahlis, N. J. Related Collections Related Article in Blood Online Social Bookmarking                   What's this?  Previous Article  |  Next Article  Submitted December 19, 2008 Accepted March 15, 2009 Influence of cytogenetics in patients with relapsed or refractory multiple myeloma treated with lenalidomide plus dexamethasone: adverse effect of deletion 17p13 Donna Reece, Kevin W. Song, Tommy Fu, Birgitte Roland, Hong Chang, Douglas E. Horsman, Adnan Mansoor, Christine Chen, Esther Masih-Khan, Young Trieu, Helene Bruyere, Douglas A. Stewart, and Nizar J. Bahlis* Division of Oncology, Princess Margaret Hospital, Toronto, Canada Division of Hematology, Vancouver General Hospital, Vancouver, Canada Celgene Corporation, Summit, NJ, United States Department of Pathology and Laboratory Medicine, University of Calgary, Calgary, Canada Department of Pathology and Laboratory Medicine, British Columbia Cancer Agency, Vancouver, Canada Division of Hematology and Transfusion Medicine, Calgary Laboratory Services, Calgary, Canada Department of Pathology and Laboratory Medicine, Vancouver General Hospital, Vancouver, Canada Division of Hematology and Bone Marrow Transplant, University of Calgary, Calgary, Canada * Corresponding author; email: nbahlis{at}ucalgary.ca. Although lenalidomide and dexamethasone is effective therapy for patients with relapsed/refractory multiple myeloma (MM), the influence of high-risk cytogenetic abnormalities on outcomes is unknown. This sub-analysis of a large, open-label study investigated the effects of the most common unfavorable cytogenetic abnormalities detected by fluorescence in situ hybridization - del(13q), t(4;14), and del(17p13) - in 130 evaluable patients treated with this regimen. While patients with either del(13q) or t(4;14) experienced a median time to progression (TTP) and overall survival (OS) comparable to those without these cytogenetic abnormalities, patients with del(17p13) had a significantly worse outcomes with a median TTP = 2.22 months (HR 2.82; P = .0014) and median overall survival OS = 4.67 months (HR 3.23; P = .0013). Improved therapeutic strategies are required for this subgroup of patients. This study was registered in Clinicaltrials.gov under number NCT00179647. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? Related Article in Blood Online: Risky business in myeloma Sagar Lonial Blood 2009 114: 496-497. [Full Text] [PDF] This article has been cited by other articles: S. Lonial Risky business in myeloma Blood, July 16, 2009; 114(3): 496 - 497. [Full Text] [PDF]

	Copyright © 2009 by American Society of Hematology         Online ISSN: 1528-0020